TSC1 and neuroendocrine neoplasm: Although both somatic TSC1 mutation [30] and mTOR mutations [31] have been reported in exceptional responders, these alterations are relatively rare in tumor types such as hormone–receptor positive breast cancer and neuroendocrine tumors, where rapalogs are commonly used.